Literature DB >> 19026801

Impact of the Maze operation on the progression of mild functional tricuspid regurgitation.

Hyung Gon Je1, Hyun Song, Sung Ho Jung, Suk Jung Choo, Jong Min Song, Duk Hyun Kang, Sung Cheol Yun, Cheol Hyun Chung, Jae Kawn Song, Jae Won Lee.   

Abstract

OBJECTIVES: In patients having mitral valve surgery, concomitant surgery for mild functional tricuspid regurgitation remains the subject of debate. This study examined the effect of Maze operation and tricuspid valve repair on postoperative functional tricuspid regurgitation progression.
METHODS: The study retrospectively analyzed 250 patients (86 men, 164 women) with mild functional tricuspid regurgitation (grade 2) who had mitral valve surgery between January 1994 and July 2006. Based on follow-up data, patients were defined as either stable (n = 209, 83.6%) or aggravated (n = 41, 16.4%). Predictors for significant tricuspid regurgitation development were identified using Cox regression analysis.
RESULTS: The mean follow-up time was 62.6 +/- 39.8 months after surgery. Although most mitral valve procedures were successful, there was an increase in the incidence of significant functional tricuspid regurgitation overall from immediately postoperative to final assessment (5.2% to 16.4%, P < 0.01). Univariate analysis showed that old age, shorter aortic crossclamping time, and omission of Maze operation were associated with functional tricuspid regurgitation progression. Multivariate analysis showed that older age (adjusted hazard ratio, 1.05; 95% confidence interval, 1.02 to 1.08), a rheumatic etiology of the mitral valve disease (adjusted hazard ratio, 2.31; 95% confidence interval, 1.21 to 4.42), and no Maze operation (adjusted hazard ratio, 7.90; 95% confidence interval, 1.90 to 32.86) were independent predictors of mild functional tricuspid regurgitation progression. For the 168 patients with preoperative atrial fibrillation, Maze operation improved the tricuspid regurgitation-free survival significantly (P < .01) but tricuspid valve repair showed no significant difference.
CONCLUSIONS: Mild functional tricuspid regurgitation can progress postoperatively despite successful mitral valve surgery. Although tricuspid valve repairs alleviate progression of functional tricuspid regurgitation, concomitant Maze operation is a more powerful protective factor against mild functional tricuspid regurgitation progression.

Entities:  

Mesh:

Year:  2008        PMID: 19026801     DOI: 10.1016/j.jtcvs.2008.08.009

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Long-term results of the Maze procedure in patients with mechanical valve.

Authors:  Yoshimori Araki; Hideki Oshima; Akihiko Usui; Yuichi Ueda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-05-11

2.  Intraoperative method based on tricuspid annular circumference in patients with mild or no tricuspid regurgitation during left-sided cardiac valve surgery for the prophylactic tricuspid annuloplasty.

Authors:  Mohammad Sharif Popal; Jin-Tao Fu; Qiu-Ming Hu; Tian-Ge Luo; Shuai Zheng; Xu Meng
Journal:  J Thorac Dis       Date:  2018-06       Impact factor: 2.895

3.  Mild-to-moderate functional tricuspid regurgitation in patients undergoing valve replacement for rheumatic mitral disease: the influence of tricuspid valve repair on clinical and echocardiographic outcomes.

Authors:  Mete Gursoy; Ali Can Hatemi
Journal:  Heart       Date:  2012-05-25       Impact factor: 5.994

4.  Survival analysis of patients with rheumatic MS after PBMV compared with MVS in a low-to-middle-income country.

Authors:  A M Ambari; B Setianto; A Santoso; B Dwiputra; B Radi; A A Alkatiri; A B Adji; E Susilowati; F Tulrahmi; M J M Cramer; P A Doevendans
Journal:  Neth Heart J       Date:  2019-11       Impact factor: 2.380

5.  Tricuspid regurgitation: clinical importance and its optimal surgical timing.

Authors:  Hyung-Kwan Kim; Seung-Pyo Lee; Yong-Jin Kim; Dae-Won Sohn
Journal:  J Cardiovasc Ultrasound       Date:  2013-03-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.